Share Price | Mineralys Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Mineralys Therapeutics, Inc. do?

Overview:Mineralys Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Net Profit: -42 Million (Quarterly Results - Mar 2025) Market Cap: USD 898.12 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.00 Return on Equity: -55.19% Price to Book: 2.63 Contact Details:Registrar Address: Not available.

Q: Is Mineralys Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Mineralys Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the RSI shows bearish conditions for both weekly and monthly periods. The Bollinger Bands reflect a mildly bullish trend on the weekly and a bullish trend on the monthly. Daily moving averages are bullish, but the KST is mildly bearish on the weekly. Dow Theory and OBV show no trend in both weekly and monthly analyses.In terms of performance, the stock has returned 208.77% year-to-date and 173.85% over the past year, significantly outperforming the S&P 500, which returned 14.18% and 17.82% respectively. Overall, the current technical stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD.

Results Declared: Mineralys Therapeutics, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.32 M

Shareholding (Dec 2025)

FII

25.57%

Held by 93 FIIs

DII

22.37%

Held by 32 DIIs

Promoter

30.02%

How big is Mineralys Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Mineralys Therapeutics, Inc. has a market capitalization of 898.12 million and reported net sales of 0.00 million with a net profit of -188.51 million over the latest four quarters. Shareholder's funds were 191.26 million, and total assets amounted to 205.90 million as of Dec 24.

View full answer

What does Mineralys Therapeutics, Inc. do?

22-Jun-2025

Mineralys Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $42 million and a market cap of $898.12 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -55.19%.

View full answer

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Mineralys Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish daily moving averages and a weekly MACD, despite bearish RSI conditions and a significant year-to-date return of 208.77% compared to the S&P 500's 14.18%.

View full answer

Compare Mineralys Therapeutics, Inc. with Similar Stocks

Agenus, Inc.Caribou Biosciences, Inc.UroGen Pharma Ltd.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,120 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-29.73%

Price to Book

3.68

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-32 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.68%

6 Months

-37.18%

1 Year

40.19%

2 Years

84.19%

3 Years

53.17%

4 Years

0.0%

5 Years

0.0%

Mineralys Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-264.46%

EBIT to Interest (avg)

-153.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.68

EV to EBIT

-8.29

EV to EBITDA

-8.29

EV to Capital Employed

-88.75

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-29.73%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 43 Schemes (22.05%)

Foreign Institutions

Held by 93 Foreign Institutions (25.57%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 34.15% vs -100.41% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-38.30",
          "val2": "-51.80",
          "chgp": "26.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.20",
          "val2": "-48.90",
          "chgp": "34.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 12.99% vs -147.29% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-170.50",
          "val2": "-192.40",
          "chgp": "11.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-154.70",
          "val2": "-177.80",
          "chgp": "12.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-38.30

-51.80

26.06%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-32.20

-48.90

34.15%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 34.15% vs -100.41% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-170.50

-192.40

11.38%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-154.70

-177.80

12.99%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 12.99% vs -147.29% in Dec 2024

All Annual Results

Company CV

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available